BIG Annual Report 2018: spreading hope

Share This Post

The Breast International Group (BIG) is pleased to present to you the 2018 Annual Report: a report with clear and timely information about its research activities, fundraising and finances, in all transparency.

In anticipation of BIG’s 20th anniversary in 2019, the 2018 annual report’s theme is “Spreading hope and progress”. Women and men diagnosed with breast cancer 20 years ago had limited treatment options and a suboptimal survival rate. Fortunately, we are making progress and mortality rates are falling thanks to the research conducted to date. 

In the feature article some of BIG’s leading researchers discuss the impact of advances in the understanding and treatment of breast cancer since 1999. They also share their view on future developments and therapies.

Progress is impossible without collaboration.
Once you choose hope, anything’s possible.

Thanks to the support and the continuous hard work of BIG’s now 59 collaborative member groups, which represent an impressive network of more than 10,000 breast cancer experts worldwide, breast cancer research continued to make significant progress in the past year. BIG’s ambition is to see the current and next generations of women and men reaping the fruits of its research to beat breast cancer.

We wish to extend our heartfelt thanks to all our member groups, partners, supporters, donors, fundraisers and staff for their tireless determination to help advance breast cancer research and treatment. Everything that we achieve is possible because we do it together.

And, just as importantly, we wish to thank and honour the 1000s of patients who participate in our trials and work with us to develop tomorrow’s cures.

More to explore

Fanny Leeb launching the campaign "One note, one donation"

One note, one donation

A new song by Fanny Leeb is being sold note by note in aid of BIG against breast cancer to support breast cancer research

Doctor analyzing medical results
Press Release

First results of MA32 trial

Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals TORONTO (Dec. 7, 2021) – A widely used and inexpensive Type 2 diabetes